No Excuse for Nonconformance - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

No Excuse for Nonconformance
An updated book provides essential information for scientists who monitor microbial quality.


Pharmaceutical Technology
Volume 33, Issue 3

Clontz is well aware of the rapid methods and dedicates a comprehensive chapter to the subject. She reviews various technical platforms that have been used for rapid methods and provides photographs of the available systems. Clontz also offers a case study for genotypically similar Staphylococci and shows the application of these new technological platforms to a practical case.

The chapter has its shortcomings, however. For example, the section about validating rapid microbiological methods should have included specific examples for a given rapid test and shown how to validate these tests against the pharmacopeial tests using diagrams of procedures. The chapter also should have explained the barriers to the use of rapid methods (e.g., expense and regulatory ambivalence) and proposed solutions.

From the standpoint of microbiological control in industry, the classical methods reign supreme because of pharmacopeial requirements. It is refreshing to see that Clontz emphasizes the classical methods of microbiology. Most of the methods discussed in the book are classical methods, modified slightly because of technical advances. These methods are used by most industrial laboratories and regulatory agencies and represent current practical applications.

The second edition of Microbial Limit and Bioburden Tests clearly and comprehensively describes microbiological tests, how to validate them, and how to interpret them. The book would be an excellent tool for training microbiologists, especially in academia. Clontz leaves microbiologists no excuses for not conforming to the compendial tests, and the book should reduce the opportunity for disagreement between pharmaceutical organizations and FDA inspectors. The new edition is a must have for industrial and regulatory microbiology laboratories.

Roger Dabbah is a principal consultant at Tri-Intersect Solutions and an associate professor of technology and engineering management at the University of Maryland, University College, Graduate School, College Park, MD 20742, tel. 301.762.9258, fax 301.762.5356,
. He is also a member of Pharmaceutical Technology's Editorial Advisory Board.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
7%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology,
Click here